Search
Menu
Zurich Instruments AG - Challenge Us 10/24 LB

Genoptix Awarded DARPA Phase I Contract

Facebook X LinkedIn Email
SAN DIEGO, May 9 -- Genoptix Inc. has received a $99,000 Phase I research and development contract, with the potential of a future Phase II contract for an additional $750,000, from the US Defense Advanced Research Projects Agency (DARPA) to use its proprietary Optophoresis technology to sort and separate complex biological, cellular or environmental samples. Optophoresis uses near-infrared laser light to simultaneously analyze and isolate specific cells based on differences in their composition, size, shape, surface chemistry and environment.

"Using our technology, we are able to measure uniquely identifiable 'optophoretic' signatures that enable us to detect and sort cells, bacteria, spores and possibly viruses," said Thomas Chung, chief scientific officer of Genoptix. "This technology thus provides higher-resolution identification and more accurate separation of biological particles than current methods. In addition, its near-infrared laser is in a biologically compatible range, leaving cells physiologically intact for further processing and research."

DataRay Inc. - ISO 11146-Compliant

Published: May 2002
Basic SciencedefenseNews & Features

We use cookies to improve user experience and analyze our website traffic as stated in our Privacy Policy. By using this website, you agree to the use of cookies unless you have disabled them.